Waypoint Bio has secured $20 million in Series A financing to advance its AI-driven cell therapy platform and move its lead solid tumor program closer to clinical testing. The New York-based biotechnology company is developing next-generation in vivo CAR T therapies using artificial intelligence, computer vision, and spatial biology. The funding round marks an important step for the company as it prepares to translate its preclinical work into early human studies.
Series A Financing and Investor Support
The financing was led by Amplify Partners, with participation from General Catalyst, Time BioVentures, Mitsui Global Investments, Lux Capital, and existing backer Hummingbird Ventures. As part of the round, Elliot Hershberg, Partner at Amplify Partners, will join Waypoint Bio’s board of directors. The investor syndicate reflects growing interest in platforms that combine AI-generated therapeutic design with experimental systems capable of testing whether those designs are likely to succeed in human biology.
Waypoint Bio said the new capital will support the advancement of its lead program, WAY-103, into an investigator-initiated clinical trial expected to begin in late 2026. The funding will also be used to expand the company’s AI and spatial biology capabilities, while strengthening its clinical development infrastructure. In addition, the company plans to continue building a broader pipeline of in vivo CAR T constructs targeting solid tumors.
Advancing AI-Designed CAR T Therapies
Waypoint Bio is focused on designing CAR T therapies for solid tumors, an area where existing cell therapy approaches have faced significant biological and clinical challenges. Unlike blood cancers, solid tumors often present barriers such as poor immune-cell infiltration, suppressive tumor microenvironments, and risks of damaging healthy tissue. Waypoint’s platform is intended to address these obstacles by evaluating therapeutic candidates in spatially complex biological settings before they move into costly clinical development.
The company’s lead candidate, WAY-103, is being developed for gastric and pancreatic solid tumors. According to Waypoint Bio, the program has shown more than 15-fold improved potency in animal models compared with multiple clinical benchmarks, while also demonstrating reduced on-target, off-tumor toxicity. The candidate was identified and optimized through pooled head-to-head screening using spatially resolved readouts that assess how each construct interacts with the tumor microenvironment.
Platform Built Around Spatial Biology
Waypoint Bio’s discovery engine integrates artificial intelligence, computer vision, and spatial pooled screening to generate and evaluate therapeutic designs. This approach allows the company to capture detailed information about how potential therapies behave across different cellular neighborhoods and local tumor environments. The resulting data are intended not only to select stronger drug candidates, but also to improve future AI models through feedback from biological validation.
Co-founder and Chief Scientific Officer David Phizicky said spatial biology has become increasingly important because it enables researchers to observe how therapeutic candidates influence local cell interactions. He noted that solid tumors require more sophisticated measurements than simple tumor-size readouts, particularly because immune suppression and infiltration barriers are central to treatment response. Waypoint Bio aims to screen for these spatial phenotypes at scale while also accounting for T cell biology, tumor microenvironment interactions, and the role of delivery vectors.
Leadership Expansion
The company also announced additions to its leadership and advisory network as it prepares for clinical development. Dr. Patrick Kaifosh, previously co-founder and Chief Scientific Officer of neuro-AI startup CTRL-Labs and Senior Director at Meta’s Reality Labs, has joined Waypoint Bio as Chief Technology Officer. His appointment is expected to strengthen the company’s capabilities in AI, automation, and technology-driven therapeutic discovery.
Waypoint Bio has also added Dr. Kristen Hege to its Scientific Advisory Board. Hege previously served as Senior Vice President of Early Clinical Development in Hematology, Oncology, and Cell Therapy at Bristol-Myers Squibb. Her experience in cell therapy development is expected to support Waypoint Bio as it advances programs toward clinical testing.
Clinical Development Plans
Beyond WAY-103, Waypoint Bio is also progressing WAY-200, a colorectal cancer program, toward the clinic with support from the Series A financing. The company is developing additional preclinical in vivo CAR T constructs for other solid tumor indications. It is also using its platform to engineer proprietary next-generation lentiviral vectors designed to improve upon current in vivo delivery systems.
Chief Executive Officer and co-founder Xinchen Wang said the company’s central focus is not simply to produce promising preclinical results, but to determine which candidates can translate into human biology and clinical benefit. He emphasized that AI can generate ideas across complex design spaces, but rigorous validation remains the limiting factor. Waypoint Bio’s strategy is to combine AI-designed candidates, spatially informed screening, and capital-efficient first-in-human studies to identify differentiated medicines with category-leading potential.
Investor Perspective
Amplify Partners’ Elliot Hershberg said the value of AI in drug development increasingly depends on the ability to test which generated ideas have real biological relevance. He described Waypoint Bio’s model as a combination of AI-generated assets, spatially resolved in vivo evaluation, and a path to rapid clinical readouts. In his view, that combination could become more powerful over time as experimental feedback improves future therapeutic design.
The financing comes as biotechnology companies increasingly seek to pair computational discovery platforms with validation systems that can generate clinically meaningful evidence. Waypoint Bio’s emphasis on spatial biology places it within a growing field focused on understanding drug effects in the context of tissue architecture and cell-to-cell interactions. For solid tumor cell therapy, that approach could be especially relevant because treatment success often depends on overcoming barriers within the tumor microenvironment.
With $20 million in new funding, Waypoint Bio is positioning itself to move from platform development toward clinical execution. Its lead program for gastric and pancreatic tumors, broader solid tumor pipeline, and vector engineering efforts give the company several paths to demonstrate the value of its AI-native discovery model. As WAY-103 approaches planned clinical entry in late 2026, Waypoint Bio’s next milestone will be showing whether its spatially informed design strategy can translate into meaningful therapeutic outcomes for patients.